Will photoimmunotherapy to fight HIV be considered safe and effective in animals by the end of 2023?
Market Rules
In 2021, researchers at the São Carlos Institute of Physics at USP (Brazil) have published good results from a technique that combines light and antibodies - the so-called photoimmunotherapy - to fight HIV (the AIDS virus). The researchers have developed a light-sensitive antibody that can bind to the virus and infected cells, and then destroy them after being stimulated with a specific light. In other words, antibodies 'armed' with light-sensitive molecules would only bind to the pre-established target, hence eliminating only the infected cells.
Further studies will still be needed to allow the use of the technique in humans. But, if the results are confirmed, the therapy could be used as a possible auxiliary tool for antiretroviral therapy.
If results from trials with animals confirm that the referred photoimmunotherapy is safe and effective against HIV by the end of 2023, indicating that tests can move forwards to human trials, this market will resolve to “Yes”.
This market will be resolved based on news (with verifiable sources) and scientific studies on the subject from sources or publications that Futuur finds credible and reputable, such as, but not restricted to, World Health Organization, Nature Magazine, Science and other specialized scientific journals.